Do you want to visit the AmgenPro website and leave Amgen.nl?
You are now leaving the Amgen Netherlands website and will be redirected to AmgenPro – the portal designed specifically for healthcare professionals. This website is only available in Dutch. Healthcare professionals who are authorized to prescribe medication, can create an account using their BIG number and will then gain access to all available information.
By selecting the Yes option, leaving Amgen.nl option you understand that you are leaving the corporate page of Amgen nl and that you will be redirected to another Internet site belonging to third parties, for whose content or opinions Amgen nl is not responsible and makes no representations regarding such content or its accuracy. By selecting this option and accessing linked third party sites, you understand that you do so at your own risk.
The website to which you will be redirected may be designed exclusively for residents of a particular country or countries, as advertised on that website. As a consequence, the website to which you will be directed may contain information on pharmaceutical products or indications that are not approved in nl. If You reside in a country other than the one to which such website is directed, please contact your local Amgen affiliate for the correct information on products in your country of residence.
Our researchers are constantly looking for medicines that can offer a solution for seriously ill patients. Clinical studies are essential for the development of these innovative medicines. In 2024, 23 Amgen studies took place in 121 different healthcare institutions in the Netherlands. A total of 1,150 patients were enrolled, of which 8 were new patients.
Do you want to know which studies? More information about Amgen's ongoing studies can be found on the www.clinicaltrials.gov website.
In addition to its own studies, Amgen also invests in third-party clinical trials. In 2024, these were 17 so-called Investigator Sponsored Studies (ISS), including DRUP, which stands for Drug Rediscovery Protocol. In DRUP, cancer patients who have little or no prospects are given medication that is actually intended for other types of cancer. It is usually too expensive to investigate whether these drugs also have an effect on other types of cancer, but due to the collaboration with hospitals and amongst others Amgen can now do this.
More information about our ISS studies can be found at:
Relevant links:
www.amgen.nl/science/klinisch-onderzoek-in-nederland/
www.clinicaltrials.gov
https://www.amgeniss.com/